John Hamm, MD
Medical Oncology · Louisville, KYNPI 1023075660
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 30.0% of the total. Reporting peaked in 2024 at $10,790 and has fallen 97.6% since, to $264 in 2025. Among medical oncology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $749.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$8K
- Novocure Inc.$5K
- Exelixis Inc.$4K
- AstraZeneca$4K
- Amgen$3K
- Puma Biotechnology, Inc.$1K
- plus $901 from 7 others
Across 590 payments — averaging $5464.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$966K
- AstraZeneca$505K
- Biontech SE$247K
- Boehringer Ingelheim International GmbH$226K
- Amgen$194K
- Seagen Inc.$184K
- plus $903K from 19 others
What the payments were for
- Consulting fees$7,19427%
- Speaking & faculty fees$15,15558%
- Travel & lodging$2,4519%
- Food & beverage$1,4335%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 5 | $7,885 |
| Novocure Inc. | 6 | $5,438 |
| Exelixis Inc. | 9 | $4,447 |
| AstraZeneca | 2 | $3,585 |
| Amgen | 2 | $2,865 |
| Puma Biotechnology, Inc. | 2 | $1,125 |
| Boehringer Ingelheim International GmbH | 1 | $485 |
| Biontech SE | 3 | $267 |
| AbbVie | 1 | $100 |
| Daiichi Sankyo Inc. | 1 | $18 |
| EMD Serono, Inc. | 1 | $16 |
| Gilead | 1 | $12 |
| Pfizer | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPZELCA$7,885
- Cabometyx$4,306
- IMFINZI$3,450
- Nerlynx$1,125
- IMDELLTRA (AMG 757)$121
How this compares
$26,245 in reported general payments places this provider in the 90th percentile of 53 medical oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 40 | $582,992 |
| RevlimidLenalidomide | 22 | $464,500 |
| TagrissoOsimertinib Mesylate | 13 | $221,099 |
| LumakrasSotorasib | 12 | $202,732 |
| JakafiRuxolitinib Phosphate | 11 | $193,062 |
| Everolimus | 13 | $33,408 |
| EliquisApixaban | 38 | $26,221 |
| Ondansetron Hcl | 138 | $3,726 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 44 | $1,810 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 67 | $1,147 |
| Morphine Sulfate ErMorphine Sulfate | 15 | $732 |
| Dexamethasone | 70 | $620 |
| Megestrol Acetate | 12 | $540 |
| Levothyroxine Sodium | 64 | $474 |
| Pantoprazole Sodium | 65 | $412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $3 | $609,21278 claims |
| AstraZenecaTagrisso | $3,585 | $221,09913 claims |
| AmgenLumakras | $2,865 | $202,73212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 53 medical oncology providers in Kentucky.
Other medical oncology in Louisville
- Emmanuel NidhiryLouisville$34K
- Renato la RoccaLouisville$24K
- Vijay RaghavanLouisville$17K
- Don StevensLouisville$16K
- Douglas NelsonLouisville$8K
- Michael DriscollLouisville$2K
- Subhash ShethLouisville$1K
- Thomas WoodcockLouisville$57
- Janell SeegerLouisville$12
- Joseph FlynnLouisville$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.